Shots:

• The EC’s approval is based on the REFLECTIONS B3281006 study assessing efficacy- safety and immunogenicity- PK/PD of Ruxience that demonstrated the bio-similarity of Ruxience of its reference product- MabThera (rituximab)
• The approval follows the CHMP’s positive opinion received in Jan’2020. The therapy is made available to the adult patients with NHL- CLL- GPA and MPA in the US along with its launch in Japan in Jan’2020
• Ruxience is a mAb- biosimilar to MabThera act by targeting CD20- present on the surface of B lymphocytes. When it attaches to CD20- rituximab aid in destroying B cells

Click here ­to­ read full press release/ article | Ref: Pfizer | Image: Pfizer